Larimar Therapeutics Q1 net loss widens slightly R&D expenses fall

Larimar Therapeutics

14/05/2026 12:08

Overview

US rare disease biotech reported Q1 net loss and lower R&D expenses yr/yr

Company advancing nomlabofusp toward rolling BLA submission for Friedreich's ataxia

Cash runway projected into Q2 2027 after $115 mln public offering in February

Outlook

Larimar plans to initiate rolling BLA submission for nomlabofusp in June 2026

Company expects to submit final BLA modules, including CMC, in second half of 2026

Larimar projects cash runway into the second quarter of 2027

Result Drivers

R&D EXPENSES - Lower research and development expenses driven by reduced nomlabofusp manufacturing and clinical trial costs, partially offset by higher consulting and personnel costs

G&A EXPENSES - Higher general and administrative expenses due to increased professional fees for commercial consulting and higher personnel costs

Company press release: ID:nGNX93gbBR

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.31
Q1 Net Income
-$29.61 mln
Q1 Income From Operations
-$31.12 mln
Q1 Operating Expenses
$31.12 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Larimar Therapeutics Inc is $13.50, about 229.3% above its May 13 closing price of $4.10

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)